Freites Martínez, Azael DavidApalla, ZoeShapiro, JerryIorizzo, MatildeRudnicka, LidiaSicco, Kristen I. LoNikolaou, VasilikiPirmez, RodrigoTakwale, AnitaFattore, DavideEt.al.2025-12-052025-12-052025Freites‐Martinez, A., Apalla, Z., Shapiro, J., Iorizzo, M., Rudnicka, L., Lo Sicco, K., Nikolaou, V., Pirmez, R., Takwale, A., Fattore, D., Dulmage, B., Piraccini, B. M., Vano‐Galvan, S., Lacouture, M., Sibaud, V., & Starace, M. V. R. (2025). Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia. Journal of the European Academy of Dermatology and Venereology, 39(12), 2039-2046. https://doi.org/10.1111/jdv.700210926-99591468-3083https://hdl.handle.net/11268/16575Persistent chemotherapy-induced alopecia (pCIA) is a distressing side effect of antineoplastic agents, imposing significant psychological burdens on cancer survivors. Despite its impact, there are no standardized guidelines for diagnosis, prevention or management. To establish consensus-based definitions, diagnostic criteria, grading systems and management recommendations for pCIA.engEfectos Colaterales y Reacciones Adversas Relacionados con MedicamentosQuimioterapiaPrevención de enfermedadesjournal article10.1111/jdv.70021embargoed accessCáncerSistema endocrinoTratamiento médicoGoal 3: Ensure healthy lives and promote well-being for all at all ages